Chicago, ILNCT06870812Now EnrollingIRB Ready

Stroke Hemorrhagic Clinical Trial in Chicago, IL

Access cutting-edge stroke hemorrhagic treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Emory University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access stroke hemorrhagic specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related stroke hemorrhagic treatment provided free

Apply for This Chicago Location

Check if you qualify for this stroke hemorrhagic clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Stroke Hemorrhagic Study in Chicago

The main purpose of this study is to compare patients with a deep bleed in the brain undergoing surgery to patients receiving routine medical care. The standard treatment involves admission to the Intensive Care Unit (ICU) with close monitoring and blood pressure control. It also includes other medical (non-surgical) treatments to prevent more bleeding or another stroke. Sometimes, doctors will recommend surgery to remove the blood if medical treatment alone is not successful. There is evidence that doing minimally invasive surgery early-using a small opening in the skull to remove blood-may help some patients. Researchers aim to understand whether this surgery is better than current medical treatment, which may include surgeries to relieve pressure on the brain in some cases. This study, called REACH, is comparing usual medical care to early minimally invasive surgery so doctors can know which is better for patients.

Sponsor: Emory University

Who Can Participate

Inclusion Criteria

Age 18-70 years
Pre-randomization head CT demonstrating an acute, spontaneous, anterior basal ganglia primary intracerebral hemorrhage (ICH) (the anterior basal ganglia include the caudate, putamen, and pallidum to the capsula externa and excludes the thalamus)
ICH volume between 20 - 80 mL as calculated by an approved and standardized volumetric measurement
Study intervention can reasonably be initiated within 24 hours after the onset of stroke symptoms. If the onset is unclear, then the onset will be considered the time that the subject was last known to be well.
Glasgow Coma Score (GCS) 5 - 14
Historical Modified Rankin Score 0 or 1

Exclusion Criteria

Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, Moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct, recurrence of a recent (less than 1 year) ICH, as diagnosed with radiographic imaging
NIH Stroke Scale (NIHSS) less than or equal to 5
Bilateral fixed dilated pupils
Extensor motor posturing
Intraventricular extension of the hemorrhage is visually estimated to involve greater than 50% of either of the lateral ventricles
Primary thalamic ICH or basal ganglia hemorrhage with involvement \> 25% of thalamus
Infratentorial intraparenchymal hemorrhage including midbrain, pontine, or cerebellar
Use of anticoagulants that cannot be rapidly reversed (i.e., criteria is met if investigators are confident that clinically significant coagulopathy is not present after targeted correction)
Evidence of active bleeding involving a retroperitoneal, gastrointestinal, genitourinary, or respiratory tract site
Uncorrected coagulopathy or known clotting disorder
Known platelet count less than 75,000 or known international normalized ratio (INR) greater than 1.4 after correction
Patients requiring long-term anti-coagulation that needs to be initiated less than or equal to 5 days from initial ICH
End-stage renal disease
Patients with a mechanical heart valve
End-stage liver disease
History of drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
Positive urine or serum pregnancy test in female subjects without documented history of surgical sterilization or post-menopausal
Known life expectancy of less than 6 months before ICH
No reasonable expectation of recovery, do-not-resuscitate (DNR), or comfort measures only before randomization
Participation in a concurrent interventional medical investigation or clinical trial. Patients in non-interventional/observational studies are eligible
Inability or unwillingness of the subject or legal guardian/representative to give written informed consent
Homelessness or inability to meet follow-up requirements

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT06870812) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Stroke Hemorrhagic Treatment Options in Chicago, IL

If you're searching for stroke hemorrhagic treatment options in Chicago, IL, this clinical trial (NCT06870812) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stroke hemorrhagic specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all stroke hemorrhagic clinical trials near you to find additional studies recruiting in your area.

More Stroke Trials in Chicago, IL

See all stroke clinical trials recruiting in Chicago — not just this study.

Browse Stroke Trials in Chicago →

Browse More Trials by Condition

Stroke TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL